Clinical trials
Conversion Therapy clinical trials
Below are recruiting conversion therapy clinical trials, each written for real people, not researchers. We’re tracking 30 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07501351RecruitingPhase 2
Comparing two therapies for advanced liver cancer after first treatment fails
This trial tests if a more intensive treatment is better than switching to another therapy for people with advanced liver cancer (HCC) that got worse after a first treatment with bevacizumab and sintilimab. It aims to find a more effective option for patients who need a next step.
Guangzhou, GuangdongAges 18–75 - NCT07560488RecruitingPhase 2
Immunotherapy and Chemotherapy Combination for Advanced Liver Cancer
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06405321Recruiting
Initial therapy before surgery for liver cancer
This trial looks at how well certain initial treatments (like targeted therapy, immunotherapy, or liver-directed procedures) work in people with liver cancer who have not had surgery yet. It aims to see if these treatments can shrink the tumor enough to allow removal later.
Nanning, ChinaAges 18–75 - NCT06949111RecruitingPhase 2
Combining radiation and chemo to make colon cancer removable
This trial tests whether giving radiation therapy along with standard chemotherapy before surgery can help shrink advanced colon cancer that has grown through the bowel wall but hasn't spread to other organs. It is for a specific type of colon cancer called pMMR/MSS.
Shijiazhuang, HebeiAges 18 years+ - NCT05837052RecruitingPhase 2
Serplulimab plus chemo after initial treatment for lung cancer
This Phase 2 study looks at how safe and effective serplulimab (an immune medicine) combined with chemotherapy is when used as a “conversion” plan—first shrinking lung cancer, then trying to remove the main tumor with surgery. It may help some people who are not initially good candidates for surgery or focused radiation to become eligible after treatment.
Hangzhou, ZhejiangAges 18–75 - NCT06709859RecruitingPhase 2
Afatinib plus chemo for unresectable stage III lung cancer
This trial tests whether combining afatinib (a targeted pill for EGFR mutations) with chemotherapy can shrink advanced stage III non-small cell lung cancer (NSCLC) enough to make surgery possible. It is for people whose cancer has not been treated yet and has a specific EGFR mutation.
Jinan, ShangdongAges 18 years+ - NCT04047953Recruiting
Chemo for stomach cancer to make tumors easier to remove
This trial tests a combination chemotherapy plan—paclitaxel (albumin-bound), oxaliplatin, and S-1 given before surgery—to try to shrink stomach cancer and improve the chance of successful tumor removal. It is for people whose cancer is locally advanced or has spread, but might still be resectable (removable) in certain cases.
Beijing, Beijing MunicipalityAges 18–75 - NCT06091423RecruitingPhase 2
XELOX plus fruquintinib and sintilimab for stomach cancer with liver or lymph node spread
This trial tests a combination of chemotherapy (XELOX), a targeted therapy (fruquintinib), and an immunotherapy (sintilimab) to shrink stomach cancer that has spread only to the liver or retroperitoneal lymph nodes. The goal is to make the cancer removable by surgery.
NanjinAges 18–75 - NCT07854600RecruitingPhase 2
Ivonescimab plus chemotherapy before surgery for bile duct cancer
This trial tests a new drug combination given before surgery to shrink bile duct cancer tumors, potentially making surgery more successful. It is for patients whose cancer is locally advanced or has spread to only a few places.
Beijing, Beijing MunicipalityAges 18–80 - NCT06215651RecruitingPhase 2
Testing cadonilimab and lenvatinib before liver cancer surgery
This study tests whether a combination of two drugs (cadonilimab and lenvatinib) can shrink liver cancer enough to make it removable by surgery for people whose cancer was previously too advanced for surgery. You may qualify if your cancer hasn't spread far, you haven't had treatment before, and your liver is still working fairly well.
Beijing, Beijing MunicipalityAges 18–75 - NCT07757165RecruitingPhase 2
Surgery after drug treatment for advanced stomach cancer
This trial is for people with advanced stomach cancer that has shrunk after initial chemotherapy or targeted therapy. It compares whether adding surgery to continued medical treatment is better than staying on medical treatment alone, with the goal of improving outcomes.
ShanghaiAges 18–75 - NCT06597526Recruiting
PET/CT scanning to guide treatment for stomach cancer with abdominal spread
This trial uses two types of PET/CT scans (FDG and FAPI) to see how well chemotherapy or other treatments work before surgery for stomach cancer that has spread to the lining of the abdomen. The goal is to find the best way to measure treatment response and help guide your care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06405139RecruitingPhase 2
Chemo combo (nanoliposomal irinotecan, oxaliplatin, capecitabine) before surgery for locally advanced colorectal cancer
This trial tests a combination of three chemotherapy drugs (nanoliposomal irinotecan, oxaliplatin, and capecitabine) given before surgery to shrink locally advanced colorectal cancer that cannot be treated with radiation. The goal is to make the tumor removable with a better chance of complete removal (R0 resection).
BeijingAges 18–70 - NCT07607873Recruiting
Transplant vs surgery after chemo for liver-only colorectal cancer
This trial compares liver transplant versus liver surgery for people whose colorectal cancer has spread only to the liver and cannot be removed initially. You would first receive chemotherapy to shrink the tumors, and if they become removable, you may be randomly assigned to have a liver transplant or standard liver surgery.
MilanAges 18 years+ - NCT04687631RecruitingPhase 3
Study drug for colorectal cancer that spread to the liver
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07549100Recruiting
Tislelizumab plus chemotherapy for advanced esophageal cancer
This trial tests whether combining tislelizumab (an immunotherapy drug) with chemotherapy can shrink advanced esophageal cancer before surgery. The goal is to help patients whose tumors are too large or invasive to operate on initially.
Jinan, ShandongAges 18–75 - NCT07519486RecruitingPhase 2
Nutrition support during cancer treatment before surgery
This trial tests whether intensive nutritional support helps patients with advanced esophageal cancer (a type of squamous cell carcinoma) respond better to treatment before surgery. The goal is to improve how well the cancer shrinks and prepare the body for a successful operation.
Chengdu, SichuanAges 18–80 - NCT07483359RecruitingPhase 2
Combination therapy for advanced liver cancer with portal vein tumor thrombus
This trial tests a combination of liver-directed chemotherapy, targeted therapy, and immunotherapy to shrink advanced liver cancer that has a blood clot in the portal vein (the main vein to the liver). The goal is to make the tumor removable by surgery.
Shenyang, LiaoningAges 18–80 - NCT07438106RecruitingPhase 2
HRS-4642 with chemo to shrink pancreatic cancer before surgery
This trial tests a new drug, HRS-4642, combined with a two-drug chemotherapy (nab-paclitaxel and gemcitabine) for people with locally advanced pancreatic cancer that has not spread. The goal is to shrink the tumor enough so it can be surgically removed.
NanjingAges 18–75 - NCT07353684RecruitingPhase 2
Adebrelimab plus apatinib with chemo for gastric cancer
This trial tests a combination of two targeted drugs (adebrelimab and apatinib) with standard chemotherapy (SOX regimen) before surgery for gastric cancer that cannot be removed right away. The goal is to shrink the tumor enough to make surgery possible.
Beijing, Beijing MunicipalityAges 18–75 - NCT05713994Recruiting
Liver cancer treatments together for unresectable liver tumors
This trial tests a combined treatment plan—chemo delivered to the liver, targeted therapy, anti-VEGF therapy, and immunotherapy—to control unresectable hepatocellular carcinoma (HCC). It may help shrink tumors or slow progression when surgery isn’t possible.
Quanzhou, FujianAges 18 years+ - NCT06382103Recruiting
Liver cancer study after surgery or pre-surgery therapy
This study looks at genetic markers in the blood of people with liver cancer who are having surgery, either right away or after some treatment first. It aims to find out why some patients do better, which could help personalize care.
ShanghaiAges Any age - NCT07194005RecruitingPhase 2
Combination therapy for HER2 1+/2+ advanced stomach cancer
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07007182RecruitingPhase 2
Treating stomach cancer spread to lymph nodes with chemo, surgery, and radiation
This trial tests a combination of chemotherapy (conversion therapy), surgery, and radiation for people with stomach cancer that has spread only to lymph nodes behind the stomach. The goal is to see if this approach can help shrink the cancer and improve outcomes.
Jinan, ShandongAges 18–75
Hear when a new Conversion Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for conversion therapy?
- Yes. Clin2 currently lists 30 recruiting conversion therapy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a conversion therapy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a conversion therapy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.